Table 2.
Body fat depots at baseline and following 24 weeks of inulin-control and inulin-propionate ester supplementation
| AT distribution (% total AT) | Inulin-control (N=15) | Inulin-propionate ester (N=17) | Inulin-propionate ester−inulin-control | p Value | ||||
|---|---|---|---|---|---|---|---|---|
| Week 0 | Week 24 | p Value | Week 0 | Week 24 | p Value | Difference (95% CI) | ||
| Subcutaneous AT | 81.3±1.9 | 80.6±1.8 | 0.002 | 76.3±1.7 | 76.0±1.6 | 0.624 | −0.59 (1.69 to 0.50) | 0.288 |
| Internal AT | 18.7±1.9 | 19.4±1.8 | 0.002 | 23.7±1.7 | 24.0±1.6 | 0.624 | −0.23 (−1.09 to 0.64) | 0.608 |
| Intra-abdominal AT | 10.6±1.3 | 11.1±1.4 | <0.001 | 13.2±1.2 | 13.1±1.1 | 0.723 | −0.46 (−0.87 to −0.05) | 0.027 |
| Abdominal | 23.1±0.9 | 22.7±0.8 | 0.300 | 21.9±0.7 | 21.6±0.7 | 0.171 | −0.23 (−0.88 to 0.42) | 0.483 |
| subcutaneous AT | ||||||||
| 1H-MRS | ||||||||
| IHCL | 7.8±2.9 | 7.4±2.5 | 0.708 | 15.8±5.0 | 11.5±3.7 | 0.061 | −0.83 (−5.04 to 3.38) | 0.699 |
| Soleus IMCL | 18.8±2.0 | 18.8±1.8 | 0.973 | 21.8±3.0 | 24.0±3.7 | 0.274 | 2.70 (−1.04 to 6.44) | 0.157 |
| Tibialis IMCL | 10.0±1.5 | 10.3±1.1 | 0.869 | 9.1±1.0 | 9.5±0.9 | 0.701 | −0.42 (−2.83 to 1.99) | 0.733 |
Mean±SEM.
IHCL was measured relative to liver water content and IMCL was measured relative to total muscle creatine signal.33
AT, adipose tissue; IHCL, intrahepatocellular lipid; IMCL, intramyocellular lipid; MRS, MR spectroscopy.